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ubclinical atherosclerosis in HIV-infected patients on highly
ctive antiretroviral treatment (HAART)
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endek1, N. Ismail2
University of Malaya, Kuala Lumpur, Kuala Lumpur, Malaysia
University of Technology MARA Sungai Buluh Campus, Sungai Buluh,
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Background: Cardiovascular disease (CVD) has become more
revalent among the HIV-infected patients. Whether or not highly
ctive antiretroviral treatment (HAART) alone directly contributes
o subclinical atherosclerosis in HIV-infected patients is contro-
ersial. We aim to determine the association between HAART and
ubclinical atherosclerosis.
Methods: All patients attending the HIV clinic in University of
alaya Medical Centre from July 2011 until January 2012 were
ncluded. Patients with symptomatic HIV, established coronary
eart disease, hypertension, dyslipidaemia and diabetes mellitus
ere excluded from the study. Patients were examined for blood
ressure and anthropometric measurements. History of tobacco
onsumption and family history of coronary artery disease were
btained. Biochemical analysis comprises oral glucose tolerance
est, full lipid proﬁles (after a 10-hour fasting), CD4 cell counts and
IV RNA viral load. Analysis of carotid intima-media wall thick-
ess (CIMT) was carried out by a single trained ultrasonographer
hroughout the study period using the high-resolution B-mode
ltrasonography. Subclinical atherosclerosis was deﬁned as the
resence of plaque (focal echogenic structure with CIMT.1.2mm),
r CIMT>0.8mm.
Results: 109 HIV-infected patients were enrolled in this study.
3 (85.3%) were on HAART and 16 (14.7%) were HAART-naive.
total of 45 (41.3%) patients had subclinical atherosclerosis and
ut of that 41 (91%) were on HAART. Subclinical atherosclerosis
as signiﬁcantly associated with age, waist circumference, total
holesterol, duration of HIV infection and duration of exposure to
AART, (p <0.05). Other signiﬁcant factors associatedwith subclin-
cal atherosclerosis were hypertension (OR=2.4; 95% CI 1.1-5.4),
igh triglyceride (OR=2.9; 95% CI 1.3-6.7) and exposure to Zidovu-
ine (OR=2.5; 95% CI 1.1-6.0). However, there were no signiﬁcant
ssociation between family history of CVD, smoking and diabetes
o subclinical atherosclerosis.
Conclusion: Both duration of HIV-infection and exposure
o HAART were associated with subclinical atherosclerosis in
IV-infected patients. When individual HAART were analyzed,
idovudine has signiﬁcant association to subclinical atherosclero-
is.
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The prevalence and characteristics of metabolic syndrome in
urban Malaysian HIV-infected patients
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Background: Cardiovascular disease (CVD) and metabolic syn-
drome (MS) have become more prevalent among the HIV-infected
patients. The purpose of this study is to describe the prevalence and
characteristics of MS among the HIV-infected patients.
Methods: All patients attending the HIV clinic in University of
Malaya Medical Centre from July 2011until January 2012 were
included. Patients with symptomatic HIV, established coronary
heart disease, hypertension, dyslipidaemia and diabetes mellitus
were excluded from the study. Patients were examined for blood
pressure and anthropometric measurements. History of tobacco
consumption, family history of CVD and history of exposure to
highly active antiretroviral treatment (HAART) were also obtained.
Biochemical analysis comprisesoral glucose tolerance test, full lipid
proﬁles (after a 10-hour fasting), CD4 cell counts and HIV RNA viral
load. MS was conﬁrmed using the Harmonized criteria (2009).
Results: 126 patients were enrolled in this study. 109 (86.5%)
were on HAART and 17 (13.5%) were HAART-naive. Prevalence
of MS observed among the HIV-infected patients was 32.5%.
The prevalence increased from 19.4% among the HIV-infected
patients under age 40 years to 43.8% for those aged more than
40 (p=0.02). HIV-infected patients with MS were more likely to
be male (OR=3.1; 95% CI:1.2-8.2) and have higher mean body
mass index (BMI) (26.3 +5.0 kg/m2; p<0.05). Higher prevalence
of MS observed in patients on HAART than HAART-naive, 33%
and 29% respectively. Patients on HAART with MS were noted
to have higher mean age (42.5 +8.5, p <0.05) and lower BMI
(mean=23.3 +3.1 kg/m2; p<0.05) compared to HAART-naive with
MS. Total cholesterol and HDL-c were (5.3 +1.0 mmol/L) and
(1.3 +0.3 mmol/L) respectively (p <0.05). Duration of HAART was
not a signiﬁcant factor for MS. When individual HAART was ana-
lyzed Ritonavir contributes to MS (OR=3.2; p =0.045).
Conclusion: There is high prevalence ofMS amongHIV-infected
patients in Malaysia. Exposure to Ritonavir may increase the risk
of developing MS. These study ﬁndings highlight the importance ofhttp://dx.doi.org/10.1016/j.ijid.2012.05.768
